Covid: Johnson & Johnson vaccine approved by the USA, and soon by the European Medicines Agency

Published by Laurent P., Alexandre G. · Published on 28 February 2021 at 15h59 · Updated on 1 March 2021 at 22h22
This Saturday February 27, 2021, the Food & Drug Administration (FDA) approved Johnson & Johnson vaccine. The approval follows after the laboratory confirmed, in an official document made public this Wednesday February 24, the effectiveness of the single-dose Covid vaccine by Johnson & Johnson on severe diseases. The vaccine has sought approval in the USA and in the European Union as well.

A new Covid vaccine is now available on the market in the USA... This Saturday February 27, 2021, the FDA, aka the Food & Drug Administration, announced they have approved Johnson & Johnson vaccine for people over the age of 18. The day after the statement, French Minister of Industry Agnès Pannier-Runacher confirms on France 3 the green light from the European Union is to be given. Furthermore, the first doses of this new vaccine are to "arrive late March-early April since there is a time period to manufacture doses".

On Wednesday February 24, the FDA confirmed the effectiveness of Johnson & Johnson vaccine on severe forms of the virus in a document made public the same day, only two days before the regulator approves the produce issuance - or not. An effectiveness assessed to 85.9% agains severe diseases in the country - according to the document -, as well as 81.7% in South Africa, and 87.6% in Brazil. The vaccine is overall effective against severe coronavirus up to 85.4% 28 days following vaccination. Against mild diseases, yet, it is 66.1% effective, as announced a few days ago.

This Thursday February 4, Johnson & Johnson announced they sought marketing approval for their Covid vaccine to the FDA for a soon marketing in the USA. Issuance has been approved this Friday February 26: "After a thorough analysis of the data, the FDA’s scientists and physicians have determined that the vaccine meets the FDA’s expectations for safety and effectiveness appropriate for the authorization of a vaccine for emergency use" Peter Marks, M.D., Ph.D., director of the FDA's Center for Biologics Evaluation and Research stated. A determining step in the fight against coronavirus.

If given the green light from the US health authorities, the vaccine will be the third one on the market, following Pfizer and Moderna. The laboratory even committed to deliver 100 million doses in the country before June 2021. The laboratory also filed marketing authorization to the European Medicines Agency.

Practical information

Comments
Refine your search
Refine your search
Refine your search
Refine your search